GlassScriptPhysician profile
Violeta Gonzalez
NPI 1376547620
$1,925.90
in general payments reported to CMS, 2019-2025
18 companies · $41.32 in 2025
The $41.32 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $465 · 2023: $590 · 2024: $227 · 2025: $41.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $333.28 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $275.89 | 2021-2024 | Rybelsus, Ozempic, Tresiba |
| Abbott Laboratories | $220.60 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $157.28 | 2021-2023 | Steglatro, Lagevrio |
| Astrazeneca Pharmaceuticals LP | $139.99 | 2021-2024 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $118.84 | 2021-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.76 | 2021-2023 | Jardiance, Tradjenta |
| Pfizer INC. | $107.60 | 2021-2024 | |
| Glaxosmithkline, LLC. | $98.45 | 2021-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $73.00 | 2021-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $62.18 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $56.63 | 2021 | |
| Medtronic, INC. | $41.32 | 2025 | Minimed 780g |
| Averitas Pharma INC. | $38.28 | 2024 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $32.45 | 2022-2024 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.65 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $15.14 | 2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.56 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violeta Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.